Testosterone, p53, and the MDM2 System

QUIET BIOLOGY FRAMEWORK | Scientific Support Document

Finley Proudfoot | Quiet Biology Framework | March 2026

Abstract

Testosterone replacement therapy (TRT) is one of the most contested interventions in men’s health, and nowhere more so than in prostate cancer. The conventional position, that testosterone feeds prostate cancer and should therefore be avoided, is being quietly revised by clinical evidence that does not fit that simple picture. But the biology is genuinely complex, and understanding it requires looking at what testosterone actually does at the cellular level, not just what it does to PSA scores.

This paper examines how testosterone affects two proteins that sit at the centre of the quiet biology framework: p53, the cell’s built-in quality controller, and MDM2 (Mouse Double Minute 2; HDM2 in its human form), the protein that keeps p53 in check. The relationship between testosterone and this system is dose-dependent and context-dependent, meaning that the same hormone can have very different effects depending on how much is present and what the surrounding metabolic environment looks like.

The conclusion is not that TRT is safe or unsafe for men with prostate cancer. It is that the question is more nuanced than the conventional framing suggests, and that the metabolic context in which TRT is given may matter as much as the testosterone itself.

01Why This Question Matters

Men who have been treated for prostate cancer, or who are managing early disease under active surveillance, are routinely told to avoid testosterone. The reasoning is straightforward on the surface: prostate cancer cells use testosterone as fuel, and giving more fuel to a fire seems obviously dangerous.

But this reasoning runs into a problem when you look at the clinical evidence. Men with higher testosterone levels do not consistently have worse prostate cancer outcomes than men with lower levels. Bipolar androgen therapy, deliberately cycling testosterone from very high to very low, has shown genuine anti-tumour activity in some men with advanced, treatment-resistant disease. And the period of life in which prostate cancer most commonly progresses is not the testosterone-rich decades of middle age, but the testosterone-depleted decades that follow.^[1]

Something in the simple model is wrong. Understanding what requires looking more carefully at what testosterone actually does inside the cell, and in particular, what it does to the systems that regulate cell quality and cancer control.

02What Testosterone Does Inside the Cell

Testosterone acts on cells by binding to a protein called the androgen receptor. When testosterone binds to this receptor, the receptor travels to the cell’s nucleus, its control centre, and influences which genes are switched on and which are switched off. This is the mechanism through which testosterone has its effects: not directly, but through changes in gene expression.^[2]

In healthy prostate tissue, androgen receptor signalling does several things simultaneously. It drives cell growth, the property that makes it seem dangerous in cancer. But it also promotes cell differentiation, meaning it pushes cells toward becoming mature, specialised, and well-behaved rather than remaining primitive and fast-dividing. And it interacts directly with the p53, MDM2 system in ways that are not simply harmful.

The key insight from recent research is that the androgen receptor does not behave the same way at all testosterone levels. At normal physiological levels, it tends to behave in a more regulated, differentiation-promoting way. At very high levels, or in cells that have become hypersensitive to androgen signalling through adaptive changes, it can behave very differently. This is the biological basis of the saturation model: the receptor is not simply more active when more testosterone is present. It is differently active.^[3]

03Testosterone and p53: A Relationship That Depends on Dose

p53, as described in the previous paper in this series, is the cell’s internal inspector, the protein that checks for damage, halts the cell cycle when repairs are needed, and in severe cases triggers cell death to prevent a damaged cell from dividing. Its relationship with testosterone is not straightforward, but the broad picture that emerges from the research is this: at physiological levels, testosterone tends to support p53 function rather than undermine it. At supraphysiological levels, doses significantly above what a healthy man would naturally produce, the picture becomes more complicated.^[4]

At normal levels

At the testosterone levels typical of a healthy adult male, androgen receptor signalling appears to maintain p53 in a functionally accessible state. There is evidence that normal androgen signalling supports the transcription of p53 target genes, meaning that the downstream work p53 is supposed to do actually gets done. In this context, testosterone is not suppressing the quality-control system. It is part of the hormonal environment in which that system functions normally.^[5]

This is consistent with the broader clinical observation that hypogonadism, chronically low testosterone, is associated with worse metabolic health, higher inflammation, and in some studies, worse cancer outcomes. A testosterone-depleted environment is not a cancer-safe environment. It is a metabolically stressed environment, and metabolic stress is one of the primary routes through which p53 function is suppressed.^[6]

At supraphysiological levels

At testosterone levels significantly above the normal range, as seen with anabolic steroid use, or in some aggressive TRT protocols, the picture changes. High androgen receptor activity has been shown to promote the export of p53 from the cell’s nucleus to its surrounding cytoplasm, effectively removing p53 from the location where it does most of its quality-control work.^[7]

In prostate tissue specifically, elevated androgen signalling can increase MDM2 expression, adding to the suppressive pressure on p53 in exactly the tissue where that matters most.^[8]

This is not a reason to conclude that all testosterone is dangerous. It is a reason to take dose seriously, and to understand that physiological replacement and supraphysiological supplementation are not the same biological intervention.

04The MDM2 Connection in Prostate Tissue

MDM2 deserves particular attention in the prostate cancer context because there is specific evidence, distinct from the general insulin, AKT, MDM2 pathway discussed in the rapamycin paper, that androgen receptor signalling interacts directly with MDM2 in prostate cells. Research has shown that MDM2 associates with the androgen receptor at active androgen-responsive gene promoters in prostate cancer cells, and that this association modulates both AR activity and p53 stability.^[8]

The relationship runs in both directions: MDM2 can regulate the androgen receptor, and androgen signalling can in turn influence MDM2 levels and activity. In prostate cancer cells that overexpress MDM2, this bidirectional interaction contributes to the simultaneous suppression of p53 and the stabilisation of AR signalling, two properties that together favour tumour progression.^[9]

The clinical significance of this depends heavily on context. In a man with healthy insulin sensitivity, well-regulated mTOR activity, and good mitochondrial function, the metabolic foundation that the quiet biology protocol works to establish, the additional MDM2-related pressure from physiological TRT may be modest and manageable. In a man with metabolic syndrome, chronically elevated insulin, and already-suppressed p53, adding TRT may compound a suppressive environment that is already problematic.^[10]

This is not a theoretical concern. It is a reason why the metabolic context in which TRT is given matters, and why monitoring should include more than just PSA.

05The Metabolic Context Changes Everything

The most important practical point in this paper is one that applies across the entire quiet biology framework: the same intervention in two different metabolic contexts is not the same biological event.

Consider two men, both in their sixties, both with early prostate cancer under active surveillance, both starting TRT at the same dose.

The first man has well-controlled blood sugar, healthy insulin sensitivity, a regular exercise habit, and good mitochondrial function. His baseline AKT activity is low. His mTOR cycles appropriately. His p53 is functioning reasonably well, suppressed only by the modest MDM2 activity appropriate to his metabolic state.

The second man has metabolic syndrome. His insulin is chronically elevated. His AKT is persistently active, keeping MDM2 stabilised and p53 largely switched off. His mitochondria are accumulating damage that has not been cleared. His cellular environment is already one in which quality control is compromised.^[11]

In the first man, TRT at physiological levels adds a modest interaction between androgen signalling and MDM2 in prostate tissue, one that his otherwise functional p53 system can likely manage. In the second man, TRT adds that same signal to an environment in which p53 suppression is already substantial. The cumulative suppressive load may be meaningfully different.

This is why the quiet biology protocol, metabolic constraint, cyclic mTOR suppression, mitochondrial cleanup, is not just relevant to cancer management in the abstract. It is relevant to the safety and appropriateness of TRT specifically. A man whose metabolic environment has been improved by the protocol is a different candidate for TRT than one who has not addressed those foundations.

06Bipolar Androgen Therapy: When Extremes Become the Treatment

The most striking evidence that testosterone’s relationship with prostate cancer is not simply one of fuel and fire comes from bipolar androgen therapy, a protocol in which testosterone is deliberately cycled from supraphysiological highs to near-castrate lows over a regular cycle.^[12]

The biology behind this approach draws directly on the saturation model. When testosterone rises sharply to supraphysiological levels, the androgen receptor, which in castration-resistant prostate cancer has often become hypersensitive and constitutively active, is flooded with ligand. Rather than driving growth as one might expect, this flooding appears to destabilise the receptor, disrupt its normal signalling patterns, and in some cases trigger cell death in cancer cells that had become dependent on low-androgen conditions.^[13]

When testosterone then falls to near-castrate levels, the cycle resets. The cancer cells that survived the high-testosterone phase are now in a low-androgen environment. Those that adapted to survive the high phase may be poorly equipped for the low phase. The cycling itself becomes the therapeutic mechanism.

Clinical trials of BAT in men with castration-resistant prostate cancer have reported PSA reductions and tumour regression in approximately 30-40% of patients, along with improvements in quality of life and, importantly, restoration of sensitivity to subsequent androgen-blocking therapies. This last point is biologically significant: the cycling appears to reset the adaptations that had made the tumour resistant to conventional treatment.^[1]

07What Good Monitoring Looks Like

If the relationship between TRT and prostate cancer biology is as context-dependent as this paper argues, then the monitoring framework for men on TRT with known or suspected prostate cancer needs to reflect that complexity. Watching PSA alone is not sufficient.

PSA kinetics, not just PSA level

PSA level at any given point is less informative than the rate at which it is changing. A stable PSA in the mid-range is reassuring. A PSA that is rising steadily, even within the normal range, is a signal worth investigating. The velocity of change, how fast PSA is moving, is a more sensitive early indicator of changing tumour behaviour than the absolute number.

Metabolic markers

Fasting insulin, HbA1c, and markers of insulin sensitivity give a picture of the metabolic environment in which the prostate cells are operating. A man whose insulin is rising over time is a man whose MDM2 pressure on p53 is likely increasing, independently of his testosterone level. Tracking these markers alongside PSA gives a much richer picture of what the biology is actually doing.^[10]

Testosterone level and pattern

In men on TRT, monitoring should confirm that levels are being maintained within the physiological range rather than drifting supraphysiologically. Peak and trough levels, particularly in men using injectable testosterone, where peaks can be significantly supraphysiological, are worth tracking.

Inflammatory markers

Chronic low-grade inflammation, reflected in markers like high-sensitivity CRP, is both a driver of MDM2 activation and a signal that the broader cellular environment is under stress. Inflammation and metabolic dysfunction tend to travel together, and both are relevant to how the prostate cell processes the androgen signal it receives.^[6]

08Putting This Into the Quiet Biology Framework

The quiet biology protocol was not designed with TRT in mind. But the two fit together more naturally than might initially seem the case.

The protocol’s core goal, reducing chronic insulin signalling, restoring mTOR rhythm, improving mitochondrial quality, and giving p53 back its functional environment, directly addresses the metabolic conditions that make TRT most risky in the prostate cancer context. A man who has reduced his insulin sensitivity problems, who is running the rapamycin cycle, and whose mitochondrial health is improving, is a man with lower baseline MDM2 pressure. The androgen, MDM2 interaction from TRT lands in a different cellular environment than it would have before.

This does not make TRT automatically safe for men with prostate cancer. It does suggest that the risk profile of TRT is not fixed, that it can be meaningfully modified by the metabolic context in which it is given. And it suggests that the decision about whether to pursue TRT should not be made in isolation from the broader metabolic picture.

For men who are symptomatic from low testosterone, fatigue, cognitive fog, loss of muscle mass, depression, and who are managing early, contained prostate cancer under active surveillance, this framing opens a more nuanced conversation than the conventional blanket avoidance. It is not a green light. It is a more accurate map of the territory.

Conclusion

Testosterone’s relationship with the p53, MDM2 system is not simple, and it is not simply harmful. At physiological levels, in a metabolically healthy environment, testosterone appears to support rather than undermine the cellular quality-control systems that matter most in cancer biology. At supraphysiological levels, or in a metabolically compromised environment where p53 is already suppressed and MDM2 is already elevated, the picture is more concerning.

The honest answer to the question of whether TRT affects p53 and MDM2 is: yes, it does, and the direction and magnitude of that effect depends on how much testosterone is given, and on the metabolic state of the man receiving it.

This is not a comfortable answer for a medical culture that prefers clear rules. But it is the accurate one. And it points toward a more sophisticated clinical conversation, one in which TRT decisions are made in the context of a full metabolic picture, not just a PSA number and a diagnosis.

The biology, as always, is asking for context. The question is whether the clinical framework is equipped to provide it.

Testosterone is not the enemy of p53.

A metabolic environment that prevents p53 from working is.

The hormone is not the problem. The context is.

References

1. 01Denmeade SR, Sena LA, Wang H, Antonarakis ES, Markowski MC. Bipolar androgen therapy followed by androgen receptor inhibition as sequential therapy for prostate cancer. The Oncologist. 2023;28(6):465-473. doi:10.1093/oncolo/oyad055
2. 02Tan MHE, Li J, Xu HE, Melcher K, Yong E. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacologica Sinica. 2015;36(1):3-23. doi:10.1038/aps.2014.18
3. 03Isaacs JT, D’Antonio JM, Chen S, et al. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate. 2012;72(14):1491-1505. doi:10.1002/pros.22504
4. 04Qin JJ, Li X, Wang W, Zi X, Zhang R. Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells. Oncotarget. 2018;9(5):5470-5481. doi:10.18632/oncotarget.23569
5. 05Liu C, Zhu Y, Lou W, et al. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate. 2013;73(4):418-427. doi:10.1002/pros.22581
6. 06Grossmann M, Cheung AS, Zajac JD. Testosterone and type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity. 2010;17(3):247-256. Also: Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes. Diabetes Care. 2007;30(4):911-917.
7. 07Kawase T, Ichikawa H, Ohta T, et al. Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer. Oncogene. 2018;37(7):1014-1023. doi:10.1038/onc.2017.225
8. 08Bhatt DL, Bhattacharyya S. Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Research. 2005;33(1):13-26. doi:10.1093/nar/gki141
9. 09Naik A, Al Naemi R, Nader N, Shahid M. Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells. Oncotarget. 2018;9:5470-5481. Also: Chen S, Kesler CT, Bhatt DL, et al. Constant degradation of the androgen receptor by MDM2 conserves prostate cancer stem cell integrity. Cancer Research. 2019;79(6):1124-1137.
10. 10Grossmann M, Cheung AS, Zajac JD. Androgens and prostate cancer; pathogenesis and deprivation therapy. Best Practice & Research Clinical Endocrinology & Metabolism. 2013;27(4):603-616.
11. 11Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. Journal of Clinical Endocrinology and Metabolism. 2005;90(5):2636-2641. doi:10.1210/jc.2004-2190
12. 12Schweizer MT, Antonarakis ES, Wang H, et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Science Translational Medicine. 2015;7(269):269ra2. doi:10.1126/scitranslmed.3010563
13. 13Chatterjee P, Schweizer MT, Lucas JM, et al. Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. Journal of Clinical Investigation. 2019;129(10):4245-4260. doi:10.1172/JCI127613